{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:26:19Z","timestamp":1793978779864,"version":"4.8.0"},"reference-count":45,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Renal cell carcinoma (RCC) is a common malignancy that metastasizes to the spine, leading to complex treatment challenges and reduced survival. The aim of this study was to evaluate the prevalence of oncological biomarkers in patients with RCC spinal metastasis and analyze how these biomarkers, along with clinical factors, impact survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with RCC spinal metastasis who were treated surgically at a single academic center between 2013 and 2024. Clinical, surgical, and treatment data were collected. Immunohistochemical analysis of the 10 most prevalent biomarkers was performed on spinal tumor specimens. Predictive modeling of overall mortality was conducted using multivariate logistic regression, decision tree, and random forest algorithms. Model performance was assessed using the area under the curve, and key interactions were identified through interaction depth analysis. Unsupervised clustering was used to stratify patients into biomarker-defined risk groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Thirty-six patients (mean age 60 years) were included in the analysis. The overall mortality rate was 61.1%, with a mean follow-up duration after diagnosis of spinal metastasis of 16.1 months. CK7 and AE1\/AE3 were the most significant predictors of mortality, with CK7-positive and AE1\/AE3-negative patients having an 80% mortality rate versus 25% in AE1\/AE3-positive patients (p &lt; 0.01). CAM5.2 and\n                      <jats:italic>KRAS<\/jats:italic>\n                      expression were associated with 100% and 80% mortality, respectively. Patients with\n                      <jats:italic>EGFR<\/jats:italic>\n                      positivity and CK7 negativity had 0% mortality (p = 0.01). Decision tree analysis identified CAM5.2, CK7, and AE1\/AE3 as key hierarchical classifiers. In the random forest analysis, CK7 and AE1\/AE3 (mean minimal depths of 2.04 and 2.34, respectively) had the highest variable importance scores (Gini p &lt; 0.01) (area under the curve: logistic regression = 0.74; decision tree = 0.72; random forest = 0.81). Unsupervised clustering stratified patients into three molecular subgroups with distinct mortality risks: cluster 1 (61.5%), cluster 2 (50.0%), and cluster 3 (66.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      Immunohistochemical biomarkers, particularly CK7, AE1\/AE3, CAM5.2, and\n                      <jats:italic>EGFR<\/jats:italic>\n                      , hold significant prognostic value in RCC spinal metastasis and can help stratify patients into high- and low-risk groups. The integration of these biomarkers into tree-based machine learning models provides interpretable data-driven decision tools to support personalized surgical and systemic treatment planning. These findings warrant validation in larger multi-institutional prospective cohorts and further analysis of biomarker interactions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2026.3.spine251351","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:01:23Z","timestamp":1786492883000},"page":"600-610","source":"Crossref","is-referenced-by-count":0,"title":["Impact of oncological biomarkers and clinical factors on survival outcomes in renal cell carcinoma with spinal metastasis: a retrospective analysis"],"prefix":"10.3171","volume":"45","author":[{"given":"Joseph","family":"Rajasekaran","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania;"},{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Karim","family":"Ghaith","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Hameed","family":"Al-Mistarehi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Khalilullah","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi N.","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"},{"name":"Meharry Medical College, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Theodore","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lubelski","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"16","key":"b1","series-title":"Cancers (Basel)","first-page":"4059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino T","year":"2022","unstructured":"Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and prevention of renal cell carcinoma. Cancers (Basel). 2022;14(16):4059. doi:10.3390\/cancers14164059"},{"issue":"3","key":"b2","series-title":"Cancer Diagn Progn","first-page":"256","article-title":"Disparities in trend of renal cell carcinoma mortality in the United States","volume":"4","author":"Doddi S","year":"2024","unstructured":"Doddi S, Rashid MH. Disparities in trend of renal cell carcinoma mortality in the United States. Cancer Diagn Progn. 2024;4(3):256\u2013263. doi:10.21873\/cdp.10317"},{"issue":"8","key":"b3","series-title":"Ann R Coll Surg Engl","first-page":"649","article-title":"The management of spinal metastases from renal cell carcinoma","volume":"91","author":"Langdon J","year":"2009","unstructured":"Langdon J, Way A, Heaton S, Bernard J, Molloy S. The management of spinal metastases from renal cell carcinoma. Ann R Coll Surg Engl. 2009;91(8):649\u2013652. doi:10.1308\/003588409X432482"},{"issue":"5","key":"b4","series-title":"Global Spine J","first-page":"517","article-title":"The challenges of renal cell carcinoma metastatic to the spine: a systematic review of survival and treatment","volume":"8","author":"Goodwin CR","year":"2018","unstructured":"Goodwin CR, Ahmed AK, Boone C,  The challenges of renal cell carcinoma metastatic to the spine: a systematic review of survival and treatment. Global Spine J. 2018;8(5):517\u2013526. doi:10.1177\/2192568217737777"},{"key":"b5","series-title":"Interdiscip Neurosurg","first-page":"23","article-title":"Spinal metastases from renal cell carcinoma: case note with an overview","author":"Hadgaonkar S","year":"2021","unstructured":"Hadgaonkar S, Zawar A, Sanghavi S, Kothari A, Sancheti P, Shyam A. Spinal metastases from renal cell carcinoma: case note with an overview. Interdiscip Neurosurg. 2021;23. doi:10.1016\/j.inat.2020.100994"},{"key":"b6","series-title":"World Neurosurg","first-page":"e502","article-title":"Radiosurgery for treatment of renal cell metastases to spine: a systematic review of the literature","volume":"109","author":"Smith BW","year":"2018","unstructured":"Smith BW, Joseph JR, Saadeh YS,  Radiosurgery for treatment of renal cell metastases to spine: a systematic review of the literature. World Neurosurg. 2018;109:e502\u2013e509. doi:10.1016\/j.wneu.2017.10.011"},{"issue":"1","key":"b7","series-title":"Life (Basel)","first-page":"24","article-title":"Immunotherapy and metastatic renal cell carcinoma: a review of new treatment approaches","volume":"12","author":"Kathuria-Prakash N","year":"2021","unstructured":"Kathuria-Prakash N, Drolen C, Hannigan CA, Drakaki A. Immunotherapy and metastatic renal cell carcinoma: a review of new treatment approaches. Life (Basel). 2021;12(1):24. doi:10.3390\/life12010024"},{"issue":"Suppl 1","key":"b8","series-title":"Eur Spine J","first-page":"S27","article-title":"Outcome of embolised vascular metastatic renal cell tumours causing spinal cord compression","volume":"22","author":"Quraishi NA","year":"2013","unstructured":"Quraishi NA, Purushothamdas S, Manoharan SR, Arealis G, Lenthall R, Grevitt MP. Outcome of embolised vascular metastatic renal cell tumours causing spinal cord compression. Eur Spine J. 2013;22(Suppl 1):S27\u2013S32. doi:10.1007\/s00586-012-2648-6"},{"key":"b9","series-title":"Clin Med Insights Oncol","first-page":"11795549241298541","article-title":"Cancer biomarkers and precision oncology: a review of recent trends and innovations","volume":"18","author":"AlDoughaim M","year":"2024","unstructured":"AlDoughaim M, AlSuhebany N, AlZahrani M,  Cancer biomarkers and precision oncology: a review of recent trends and innovations. Clin Med Insights Oncol. 2024;18:11795549241298541. doi:10.1177\/11795549241298541"},{"issue":"1","key":"b10","series-title":"Signal Transduct Target Ther","first-page":"132","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J,  Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):132. doi:10.1038\/s41392-024-01823-2"},{"issue":"5","key":"b11","series-title":"Explor Target Antitumor Ther","first-page":"941","article-title":"Biomarkers in renal cell carcinoma and their targeted therapies: a review","volume":"4","author":"Gupta S","year":"2023","unstructured":"Gupta S, Kanwar SS. Biomarkers in renal cell carcinoma and their targeted therapies: a review. Explor Target Antitumor Ther. 2023;4(5):941\u2013961. doi:10.37349\/etat.2023.00175"},{"issue":"6","key":"b12","series-title":"J Formos Med Assoc","first-page":"463","article-title":"Natural history of renal cell carcinoma: an immunohistochemical analysis of growth rate in patients with delayed treatment","volume":"115","author":"Zhang L","year":"2016","unstructured":"Zhang L, Yao L, Li X, Jewett MAS, He Z, Zhou L. Natural history of renal cell carcinoma: an immunohistochemical analysis of growth rate in patients with delayed treatment. J Formos Med Assoc. 2016;115(6):463\u2013469. doi:10.1016\/j.jfma.2015.05.003"},{"issue":"1","key":"b13","series-title":"Soc Int Urol J","first-page":"43","article-title":"Promising biomarkers in renal cell carcinoma","volume":"2","author":"Kapoor J","year":"2021","unstructured":"Kapoor J, Claps F, Mir MC, Ischia J. Promising biomarkers in renal cell carcinoma. Soc Int Urol J. 2021;2(1):43\u201352. doi:10.48083\/TNGM4076"},{"issue":"7","key":"b14","series-title":"Nat Genet","first-page":"751","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis S","year":"2012","unstructured":"Pe\u00f1a-Llopis S, Vega-Rub\u00edn-de-Celis S, Liao A,  BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751\u2013759. doi:10.1038\/ng.2323"},{"issue":"29","key":"b15","series-title":"Oncotarget","first-page":"46528","article-title":"Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies","volume":"7","author":"Ma F","year":"2016","unstructured":"Ma F, Dai L, Wang Z, Zhou L, Niu Y, Jiang N. Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies. Oncotarget. 2016;7(29):46528\u201346535. doi:10.18632\/oncotarget.10225"},{"key":"b16","series-title":"Dis Markers","first-page":"4708154","article-title":"combined immunohistochemistry for the \"three 7\" markers (CK7, CD117, and Claudin-7) is useful in the diagnosis of chromophobe renal cell carcinoma and for the exclusion of mimics: diagnostic experience from a single institution","volume":"2019","author":"Zhou J","year":"2019","unstructured":"Zhou J, Yang X, Zhou L, Zhang P, Wang C. combined immunohistochemistry for the \"three 7\" markers (CK7, CD117, and Claudin-7) is useful in the diagnosis of chromophobe renal cell carcinoma and for the exclusion of mimics: diagnostic experience from a single institution. Dis Markers. 2019;2019:4708154. doi:10.1155\/2019\/4708154"},{"issue":"4","key":"b17","series-title":"Histopathology","first-page":"608","article-title":"Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells","volume":"74","author":"Gonzalez ML","year":"2019","unstructured":"Gonzalez ML, Alaghehbandan R, Pivovarcikova K,  Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells. Histopathology. 2019;74(4):608\u2013617. doi:10.1111\/his.13791"},{"issue":"7","key":"b18","series-title":"Am J Surg Pathol","first-page":"1051","article-title":"Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1\/AE3 immunostaining","volume":"32","author":"Weinbreck N","year":"2008","unstructured":"Weinbreck N, Marie B, Bressenot A,  Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1\/AE3 immunostaining. Am J Surg Pathol. 2008;32(7):1051\u20131059. doi:10.1097\/PAS.0b013e3181609d7d"},{"issue":"4","key":"b19","series-title":"Arch Pathol Lab Med","first-page":"391","article-title":"Renal cell carcinoma with clear cell and papillary features","volume":"136","author":"Ross H","year":"2012","unstructured":"Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med. 2012;136(4):391\u2013399. doi:10.5858\/arpa.2011-0479-RA"},{"issue":"37","key":"b20","series-title":"Medicine (Baltimore)","first-page":"e17104","article-title":"High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis","volume":"98","author":"He S","year":"2019","unstructured":"He S, Peng J, Li L,  High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis. Medicine (Baltimore). 2019;98(37):e17104. doi:10.1097\/MD.0000000000017104"},{"issue":"4","key":"b21","series-title":"J Kidney Cancer VHL","first-page":"40","article-title":"Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma","volume":"1","author":"Bayrak O","year":"2014","unstructured":"Bayrak O, Sen H, Bulut E,  Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma. J Kidney Cancer VHL. 2014;1(4):40\u201345. doi:10.15586\/jkcvhl.2014.10"},{"issue":"8","key":"b22","series-title":"Int J Colorectal Dis","first-page":"1781","article-title":"KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis","volume":"36","author":"Peng J","year":"2021","unstructured":"Peng J, Lv J, Peng J. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis. Int J Colorectal Dis. 2021;36(8):1781\u20131790. doi:10.1007\/s00384-021-03911-z"},{"issue":"7","key":"b23","series-title":"Br J Cancer","first-page":"1266","article-title":"Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma","volume":"89","author":"Kallio JP","year":"2003","unstructured":"Kallio JP, Hirvikoski P, Helin H,  Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer. 2003;89(7):1266\u20131269. doi:10.1038\/sj.bjc.6601241"},{"issue":"2","key":"b24","series-title":"Ann Surg Oncol","first-page":"694","article-title":"Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status","volume":"23","author":"Shin SJ","year":"2016","unstructured":"Shin SJ, Jeon YK, Kim PJ,  Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23(2):694\u2013702. doi:10.1245\/s10434-015-4903-7"},{"issue":"1","key":"b25","series-title":"Mol Cancer","first-page":"146","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu Z","year":"2024","unstructured":"Zhu Z, Jin Y, Zhou J,  PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. 2024;23(1):146. doi:10.1186\/s12943-024-02059-y"},{"issue":"2","key":"b26","series-title":"Cell","first-page":"291","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley KA","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T,  Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291\u2013304.e6. doi:10.1016\/j.cell.2018.03.022"},{"issue":"4","key":"b27","series-title":"Appl Immunohistochem Mol Morphol","first-page":"274","article-title":"Cluster analysis according to immunohistochemistry is a robust tool for non-small cell lung cancer and reveals a distinct, immune signature-defined subgroup","volume":"28","author":"Sterlacci W","year":"2020","unstructured":"Sterlacci W, Fiegl M, Juskevicius D, Tzankov A. Cluster analysis according to immunohistochemistry is a robust tool for non-small cell lung cancer and reveals a distinct, immune signature-defined subgroup. Appl Immunohistochem Mol Morphol. 2020;28(4):274\u2013283. doi:10.1097\/PAI.0000000000000751"},{"key":"b28","series-title":"Front Cell Dev Biol","first-page":"550","article-title":"Identification and validation of the immune subtypes of lung adenocarcinoma: implications for immunotherapy","volume":"8","author":"Song Y","year":"2020","unstructured":"Song Y, Yan S, Fan W,  Identification and validation of the immune subtypes of lung adenocarcinoma: implications for immunotherapy. Front Cell Dev Biol. 2020;8:550. doi:10.3389\/fcell.2020.00550"},{"issue":"1","key":"b29","series-title":"Eur Respir J","first-page":"2101674","article-title":"Prognostic phenotypes of early-stage lung adenocarcinoma","volume":"60","author":"Lamort A-S","year":"2022","unstructured":"Lamort A-S, Kaiser JC, Pepe MAA,  Prognostic phenotypes of early-stage lung adenocarcinoma. Eur Respir J. 2022;60(1):2101674. doi:10.1183\/13993003.01674-2021"},{"issue":"6","key":"b30","series-title":"Cancer Sci","first-page":"1763","article-title":"Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments","volume":"115","author":"Fukuda H","year":"2024","unstructured":"Fukuda H, Arai K, Mizuno H,  Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. Cancer Sci. 2024;115(6):1763\u20131777. doi:10.1111\/cas.16154"},{"key":"b31","series-title":"Front Oncol","first-page":"1023833","article-title":"A signature-based classification of lung adenocarcinoma that stratifies tumor immunity","volume":"12","author":"Zhang X","year":"2022","unstructured":"Zhang X, Jiang D, Li S, Zhang X, Zheng W, Cheng B. A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. Front Oncol. 2022;12:1023833. doi:10.3389\/fonc.2022.1023833"},{"issue":"25","key":"b32","series-title":"J Clin Oncol","first-page":"2957","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell WK","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ,  Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022;40(25):2957\u20132995. doi:10.1200\/JCO.22.00868"},{"issue":"6","key":"b33","series-title":"Cancer Sci","first-page":"2416","article-title":"Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases","volume":"112","author":"Kato S","year":"2021","unstructured":"Kato S, Demura S, Murakami H,  Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases. Cancer Sci. 2021;112(6):2416\u20132425. doi:10.1111\/cas.14902"},{"key":"b34","series-title":"Front Oncol","first-page":"659779","article-title":"Clinical characteristics and prognosis of renal cell carcinoma with spinal bone metastases","volume":"11","author":"Zhai J","year":"2021","unstructured":"Zhai J, Liu N, Wang H, Huang G, Man L. Clinical characteristics and prognosis of renal cell carcinoma with spinal bone metastases. Front Oncol. 2021;11:659779. doi:10.3389\/fonc.2021.659779"},{"issue":"1","key":"b35","series-title":"J Neurosurg Spine","first-page":"108","article-title":"Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma","volume":"20","author":"Tatsui CE","year":"2014","unstructured":"Tatsui CE, Suki D, Rao G,  Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma. J Neurosurg Spine. 2014;20(1):108\u2013116. doi:10.3171\/2013.9.SPINE13158"},{"issue":"2","key":"b36","series-title":"Neurosurg Focus","first-page":"E13","article-title":"Factors associated with improved survival following surgery for renal cell carcinoma spinal metastases","volume":"41","author":"Petteys RJ","year":"2016","unstructured":"Petteys RJ, Spitz SM, Goodwin CR,  Factors associated with improved survival following surgery for renal cell carcinoma spinal metastases. Neurosurg Focus. 2016;41(2):E13. doi:10.3171\/2016.5.FOCUS16145"},{"issue":"10","key":"b37","series-title":"Eur Spine J","first-page":"2142","article-title":"Tokuhashi score is predictive of survival in a cohort of patients undergoing surgery for renal cell carcinoma spinal metastases","volume":"24","author":"Petteys RJ","year":"2015","unstructured":"Petteys RJ, Spitz SM, Rhee J,  Tokuhashi score is predictive of survival in a cohort of patients undergoing surgery for renal cell carcinoma spinal metastases. Eur Spine J. 2015;24(10):2142\u20132149. doi:10.1007\/s00586-015-3862-9"},{"issue":"12","key":"b38","series-title":"Spine J","first-page":"2753","article-title":"Predicting survival outcomes in renal cell carcinoma spinal metastases: a multicenter evaluation of existing prognostic systems","volume":"25","author":"Li Z","year":"2025","unstructured":"Li Z, Wei F, Hu J,  Predicting survival outcomes in renal cell carcinoma spinal metastases: a multicenter evaluation of existing prognostic systems. Spine J. 2025;25(12):2753\u20132764. doi:10.1016\/j.spinee.2025.05.025"},{"issue":"6","key":"b39","series-title":"Cancers (Basel)","first-page":"1595","article-title":"The role of surgery in spinal intradural metastases from renal cell carcinoma: a literature review","volume":"14","author":"Corvino S","year":"2022","unstructured":"Corvino S, Mariniello G, Solari D, Berardinelli J, Maiuri F. The role of surgery in spinal intradural metastases from renal cell carcinoma: a literature review. Cancers (Basel). 2022;14(6):1595. doi:10.3390\/cancers14061595"},{"issue":"9","key":"b40","series-title":"Bone Joint J","first-page":"1241","article-title":"Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma","volume":"100-B","author":"Higuchi T","year":"2018","unstructured":"Higuchi T, Yamamoto N, Hayashi K,  Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint J. 2018;100-B(9):1241-1248. doi:10.1302\/0301-620X.100B9.BJJ-2017-1163.R3"},{"key":"b41","series-title":"Crit Rev Oncol Hematol","first-page":"19","article-title":"Treatment of spinal metastases in renal cell carcinoma: a critical review","volume":"125","author":"Teyssonneau D","year":"2018","unstructured":"Teyssonneau D, Gross-Goupil M, Domblides C,  Treatment of spinal metastases in renal cell carcinoma: a critical review. Crit Rev Oncol Hematol. 2018;125:19\u201329. doi:10.1016\/j.critrevonc.2018.02.017"},{"issue":"10","key":"b42","series-title":"Diagnostics (Basel)","first-page":"2442","article-title":"Clear cell renal cell carcinoma spinal metastases: which factors matter to the overall survival? A 10-year experience of a high-volume tumor spine center","volume":"12","author":"Terzi S","year":"2022","unstructured":"Terzi S, Pipola V, Griffoni C,  Clear cell renal cell carcinoma spinal metastases: which factors matter to the overall survival? A 10-year experience of a high-volume tumor spine center. Diagnostics (Basel). 2022;12(10):2442. doi:10.3390\/diagnostics12102442"},{"issue":"6","key":"b43","series-title":"Neurosurgery","first-page":"1174","article-title":"Survival after surgery for renal cell carcinoma metastatic to the spine: impact of modern systemic therapies on outcomes","volume":"87","author":"Shankar GM","year":"2020","unstructured":"Shankar GM, Van Beaver LA, Choi BD,  Survival after surgery for renal cell carcinoma metastatic to the spine: impact of modern systemic therapies on outcomes. Neurosurgery. 2020;87(6):1174\u20131180. doi:10.1093\/neuros\/nyaa224"},{"issue":"4","key":"b44","series-title":"J Neurosurg Spine","first-page":"529","article-title":"Predicting tumor-specific survival in patients with spinal metastatic renal cell carcinoma: which scoring system is most accurate?","volume":"33","author":"Massaad E","year":"2020","unstructured":"Massaad E, Hadzipasic M, Alvarez-Breckenridge C,  Predicting tumor-specific survival in patients with spinal metastatic renal cell carcinoma: which scoring system is most accurate? J Neurosurg Spine. 2020;33(4):529\u2013539. doi:10.3171\/2020.4.SPINE20173"},{"issue":"5","key":"b45","series-title":"Cytopathology","first-page":"562","article-title":"Immunocytochemistry for diagnostic cytopathology\u2014a practical guide","volume":"32","author":"Kanber Y","year":"2021","unstructured":"Kanber Y, Pusztaszeri M, Auger M. Immunocytochemistry for diagnostic cytopathology\u2014a practical guide. Cytopathology. 2021;32(5):562\u2013587. doi:10.1111\/cyt.12993"}],"container-title":["Journal of Neurosurgery: Spine"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/45\/4\/article-p600.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/45\/4\/article-p600.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/45\/4\/article-p600.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:50:03Z","timestamp":1793976603000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/45\/4\/article-p600.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":45,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2026.3.spine251351","relation":{},"ISSN":["1547-5654"],"issn-type":[{"value":"1547-5654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}